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Purpose: To evaluate the safety and efficacy of oral Apatone® (Vitamin C and Vitamin K3) administration in the 
treatment of prostate cancer in patients who failed standard therapy.   
Materials and Methods: Seventeen patients with 2 successive rises in PSA after failure of standard local therapy 
were treated with (5,000 mg of VC and 50 mg of VK3 each day) for a period of 12 weeks. Prostate Specific Antigen 
(PSA) levels, PSA velocity (PSAV) and PSA doubling times (PSADT) were calculated before and during 
treatment at 6 week intervals. Following the initial 12 week trial, 15 of 17 patients opted to continue treatment for 
an additional period ranging from 6 to 24 months. PSA values were followed for these patients.  
Results: At the conclusion of the 12 week treatment period, PSAV decreased and PSADT increased in 13 of 17 
patients (p ≤ 0.05). There were no dose-limiting adverse effects. Of the 15 patients who continued on Apatone 
after 12 weeks, only 1 death occurred after 14 months of treatment.  
Conclusion: Apatone showed promise in delaying biochemical progression in this group of end stage prostate 
cancer patients. 
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Introduction  
The PSA era has led to a stage migration in the 
clinical course of prostate cancer. While this success 
has dramatically lowered the death rate from prostate 
cancer, it remains the most common cancer in men 
with 234,460 new cases and 27,350 deaths in the US in 
2007.1 While hormonal therapy is typically initiated 
when the disease has advanced beyond local 
involvement and delays the time to PSA recurrence, it 
has not improved overall survival2 of patients with 
metastatic disease and has significant side effects.3 
Newer chemotherapeutic regimens for metastatic 
prostate cancer show promise,4  but there are few 
therapy options for androgen independent prostate 
cancer (AIPC) patients. Therefore, there is a substantial 
need for new therapeutic options. 
Because of their relatively low systemic toxicity, 
vitamin C (VC) and vitamin K3 (VK3), have been 
evaluated for their abilities to prevent and treat 
cancer.5 VC exhibited selective toxicity against a 
variety of malignant cell lines, prevented the induction 
of experimental tumors, acted as a chemosensitizer, 
and acted in vivo as a radiosensitizer. However, 
variable clinical results were obtained with VC 
because of the difficulty of attaining clinically active 
doses.6 VK3 exhibited selective antitumor activity alone 
and in conjunction with many chemotherapeutic 
agents in human cancer cell lines. However, while 
intravenous VK3 acted as a chemosensitizing and 
radiosensitizing agent in patients, 30% of the patients 
exhibited hematologic toxicity (at higher doses).7 
When VC and VK3 were combined in a ratio of 100:1 
(Apatone) and administered to human tumor cell lines, 
including androgen independent prostate cancer cells 
(DU145), they exhibited a synergistic inhibition of cell 
growth and induced cell death by apoptosis at 
concentrations that were 10 to 50 times lower than for 
the individual vitamins.8, 9, 10 In addition, oral Apatone 
significantly (P << 0.01) increased the mean survival 
time of nude mice inoculated i.p. with DU145 cells and 
significantly reduced the growth rate of solid tumors 
i n  n u d e  m i c e  ( P  < 0.05) without inducing any 
significant bone marrow toxicity, changes in organ 
weight or pathologic changes of these organs.9  
The purpose of this study was to evaluate the 
safety and efficacy of oral Apatone  administered 
throughout the day in prostate cancer in patients who 
failed standard therapy.  Int. J. Med. Sci. 2008, 5 
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Materials and Methods  
Patient selection 
Prostate cancer patients who had failed standard 
therapy were enrolled at William Beaumont, Royal 
Oak, MI and Summa Health Systems, Akron, OH. 
Standard therapy was defined to include radical 
prostatectomy, radiotherapy and hormonal ablation. 
We did not include docetaxol chemotherapy in our 
inclusion criteria for failure of standard therapy. A 
patient was required to have a biopsy with proven 
prostate cancer and 2 successive rises in PSA to be 
included in the study. The patient could not be 
currently undergoing chemotherapy, radiotherapy, or 
androgen deprivation.  
All patients exhibited acceptable renal function 
with blood urea nitrogen lower than 40 mg/dl and 
creatinine levels lower than 3 mg/dl and lacked 
clinical signs of obstructive liver disease as 
demonstrated by SGOT levels below 75 U/l; SGPT 
levels below 80 U/l and Alkaline Phosphatase levels 
below 200 U/l. TPatients using anticoagulants, 
chemotherapeutic agents, vitamin K, or vitamin C 
were excluded from the study. This protocol was 
reviewed and approved by the Institutional Review 
Board, and all patients provided their voluntary, 
written informed consent. 
Evaluations 
 Each subject was interviewed by the study 
coordinator and examined by an urologist. 
Pretreatment evaluation included: a complete history 
and physical examination with a digital rectal 
examination for prostate configuration, size and 
symmetry; a medication audit; AUA Pain Scale and 
Symptom Score analysis; a complete blood count with 
differential, comprehensive chemistry panel including 
liver and renal panel, coagulation studies and a PSA 
test. We did not include standard bone scans or other 
radiographic studies as part of our study protocol. 
Patients were always seen by the study coordinator 
and the same examining urologist.   
Treatment 
All patients were treated with Vitamin C: K3 
(5,000 mg. of VC and 50 mg. of VK3 each day, Apatone) 
for a total of 12 weeks. Apatone in capsular form (500 
mg VC as ascorbate and 5mg VK3 as bisulfite) at a dose 
of 2 capsules on arising, then 1 capsule every two 
hours for six doses followed by two capsules at 
bedtime for a total of ten capsules per day. Following 
the 12 week study, two of the three “non-responders” 
in the study who had large body mass index values 
were given double the dose of Apatone by doubling 
the number of capsules in the previous regimen.  
Analysis of PSA changes and Statistics 
PSA velocity (PSAV) and doubling time (PSADT) 
were calculated using the Prostate Cancer Research 
Institute Algorithms.12 Successful outcome was 
considered a PSADT increase and a PSAV decrease. 
The binomial expansion was used to calculate the exact 
probability of the number of successful outcomes 
among the enrolled patients. A probability of p <0.05 
was taken as indicative of an Apatone effect. Matched 
t-tests were employed to test for significant difference 
in PSA velocity and doubling times before and after 
treatment.13 L i n e a r  s p l i n e  f i t  a n a l y s i s  w a s  u s e d  t o  
measure and compare PSA values before, during and 
after therapy.12  
Results  
Of thirty-three patients approached for 
participation, fourteen were not eligible; one 
withdrew; and one did not have two documented PSA 
values prior to enrollment. The characteristics of the 
remaining seventeen patients are detailed in Table 1. 
The median patient age was 71.5 (range 56 – 85 years), 
AUA performance status 6.5 (range 1 – 14) and median 
number of prior chemotherapy regimens was two. 
Table 1. Patient Characteristics 
N = 17   
Age: median (range)  74.5 (56 – 85) 
AUA Symptom Score: median (range)  6 (1 – 14) 
Race:   
 Caucasian  15 
 African American   1 
Prior therapies (1 or more treatments):   
 Hormonal  10 
 Radiation   8 
 Surgery   17  
Chemotherapy:   
 None   0 
 One   0 
 Two   0  
 Three or more   1 
 
Pre-treatment PSAV ranged from 1.05 to 696 
ng/ml/year (median 21.6 ng/ml/yr), while in-trial 
PSAV ranged from -12 to 256 ng/ml/year (median 
6.39 ng/ml/yr). Conversely, pre-treatment PSADT 
values ranged from 2.0 to 54.4 months (median 3.12 
months), while in-trial PSADT values ranged from -39 
to 57.1 months (median 7.88 months). 
Linear spline fit analysis was performed using 
PSA levels before treatment, during treatment and 
following treatment (Figure 1). Representative curves 
are shown for a patient with a pre-treatment PSA > 30 
ng/ml (Fig. 1a), a patient with 30 ng/ml > PSA > 10 
ng/ml (Fig. 1b) and for a patient with a PSA < 10 
ng/ml (Fig. 1c). In all 3 cases, the rate of PSA increase 
is significantly decreased during Apatone treatment, Int. J. Med. Sci. 2008, 5 
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but increases at a rate similar to that seen before 
treatment once treatment ended (Fig. 1a and 1b). 
Thirteen of the 17 patients had a successful outcome; a 
decrease in PSAV and a lengthening of PSDT (Table 2). 
The probability of 13/17 successful outcomes is 0.008 
suggesting the 76 % response we observed, was 
unlikely due to chance. The 3 “non-responders” each 
volunteered to have their dose of Apatone doubled 
following the trial. There were no adverse effects and 
two of these three patients subsequently had a 
decrease in PSA velocity and increase in PSA doubling 
time. No patient had a significant decrease in absolute 
PSA.
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Figure 1. Natural Log transformations of PSA measurements for patients with PSA greater than 30ng/ml (a); between 10-30ng/ml 
(b) and less than 10ng/ml (c). Before and after treatment with Apatone plotted against time in weeks fitted with a linear spline with 
knots at -60 weeks, the start of Apatone therapy and end of therapy. (Æ) indicate where patients went off Apatone or started 
alternative therapy. 
 
Table 2. PSA Velocity and Doubling Time in Months 
PSA Velocity  PSA Doubling Time 
 
 
Patient 
Pre-trial 
 
In-trial Change Pre-trial  In-trial Change 
1  1.74  - 12.0  Decreased   54.4  - 5.86  Increased 
2   26.1   - 3.01  Decreased   2.51   - 21.2  Increased 
3   257   158  Decreased   3.00  6.30  Increased 
4   14.6  9.14  Decreased   27.6  57.05  Increased 
5 4.38  3.65  Decreased    2.76  9.17  Increased 
6   19.3   - 8.11  Decreased   12.1   - 39.5  Increased 
7   9.95   2.74  Decreased   2.72   13.7  Increased 
8   1.05   0.00  Decreased   10.6  > 60  Increased 
9   696  256  Decreased   2.03   9.24  Increased 
10   46.5   12.6  Decreased   3.23   20.4  Increased 
11   0   0  Unchanged   0   0.00  Unchanged 
12   2.09   0.00  Decreased   5.23  > 60  Increased 
13   352  163  Decreased   2.79   8.90  Increased 
14   21.1   81.7  Increased   7.24   4.30  Decreased 
15   54.2   112  Increased   2.91   2.88  Decreased 
16   22.0   30.9  Increased   6.54   6.58  Increased 
 
 
Following the 12 week trial, 15 of 17 patients 
opted to continue Apatone therapy. Any decision to 
remain on Apatone therapy was left entirely to the 
patient. Anecdotally, most patients reported feeling 
“better” and more “energetic.” This coupled with 
stabilization of rising PSA along with no significant 
side effects led the men to continue therapy. Four 
continued therapy for 6 months and 11 continued for 
at least 1 year with one patient continuing for more 
than 2 years. Therapy was not discontinued in any 
patient due to vitamin toxicity or for other safety 
reasons. The PSA values of these patients were 
checked at various intervals while on treatment and 
remained stable. Patients terminating Apatone therapy 
experienced sharp increases in PSA levels as seen in 
the linear spline fit analysis (Figure 1). Of the 11 Int. J. Med. Sci. 2008, 5 
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patients on therapy for greater than 1 year, only one 
(initial PSA 256, PSADT= 3 months, and PSAV 
157ng/ml/yr) passed away after 14 months.  
No noteworthy changes were observed in the 
patient’s complete blood counts, biochemistry panels 
or coagulation studies. No dose limiting toxicity or 
adverse events were experienced. Mild intermittent 
gastro-esophageal reflux symptoms was observed in 
16 of 17 patients, but was eliminated when the 
Apatone was taken with meals or with antacids. The 
average AUA symptom score prior to beginning 
therapy was 7.9 (Table 3). This fell to 7.2 upon 
completion of the 12 week trial (P = .07). The average 
pain score based on the standard index was 3.2 
initially, 2.3 at 6 weeks and returned to 3.2 at twelve 
weeks (Table 4). 
Table 3. AUA Symptom Scores 
AUA Score 
In Points 
Number of 
Patients 
Initial 
Visit 
Six Week 
Visit 
Twelve 
Week Visit 
Mild (0-7)  7   4.14 ± 
0.40† 
4.27 ± 
0.51 
3.43 ± 0.53 
Moderate 
(8-19) 
9 10.9  ± 
0.71 
12.0 ± 
0.21 
10.0 ± 0.80 
Severe 
(20-35) 
0 --  --  -- 
† = Data expressed as the mean ± standard error of the mean 
Table 4. Pain Scores 
AUA Pain 
Score 
In Points 
Initial 
Visit 
Six Week 
Visit 
Twelve Week 
Visit 
  3.19 ± 0.79†  2.31 ± 0.66  3.19 ± 0.70 
† = Data expressed as the mean ± standard error of the mean 
  
Discussion 
In a previously published, prospective, 
randomized trial, patients with pathologically proven 
prostate cancer in advanced stages (M1), osseous 
metastasis and resistance to hormone therapy were 
given two, 7 day courses of oral Apatone (VC at 5 
g/m2/day and VK3 at 50 mg/m2/day), VC alone, VK3 
alone, or a placebo.14 The 7day courses of treatment 
occurred during the first and fourth week of the study 
with two weeks of follow up after each treatment 
period. For the vitamin combination, homocysteine (a 
marker of tumor cell death induced by Apatone) 
assays showed an immediate and statistically 
significant drop (p<<0.01) in tumor cell numbers, 
while PSA serum levels rose in the two initial weeks 
and then fell to levels that were significantly different 
(p << 0.01) from the control group. For VC and VK3 
alone, a non-significant difference was observed 
between the serum levels of homocysteine and PSA 
compared to the control group which suggested that 
the decreased PSA levels were due to tumor cell 
death.14 In this study, Apatone was administered daily 
in a single oral dose which was 2.5 to 3 times higher 
than the dose employed during the initial 12 weeks of 
our study. This dose resulted in a significant decrease 
in patient PSA levels which was ascribed to Apatone- 
induced tumor cell death by autoschizis. Conversely, 
the lower Apatone doses employed in the current 
study, led to increased PSADT without decreasing 
patient PSA levels. 
In the previous study, Apatone was given in a 
single daily dose.14 However, Apatone was designed 
as an adjunctive therapy for existing treatment 
regimens with Apatone being administered 
intravenously in a bolus immediately prior to 
chemotherapy or radiotherapy and then in daily oral 
maintenance doses between therapies to prevent 
tumor growth following washout of the 
chemotherapeutic agent. In addition, pharmacokinetic 
studies indicated serum vitamin C levels returned to 
steady-state values within 5 to 6 hours of oral 
administration.15 For these reasons, Apatone was given 
every 5 to 6 hours in this study. During the 12 week 
course of the study, PSADT was the primary endpoint. 
Using this criterion, thirteen of 17 patients had 
significant increases in PSA doubling time. Following 
the initial 12 week trial, two of the three 
“non-responders” in the study who had large body 
mass index values were given increased Apatone 
doses adjusted to compensate for their elevated BMI 
values. Both patients subsequently became 
“responders”. In addition, 15 of 17 patients opted to 
continue Apatone therapy following the 12 week trial. 
The PSA values of these patients were checked at 
various intervals while on treatment and remained 
stable. Therapy was not discontinued in any patient 
due to vitamin toxicity or for other safety reasons.  
PSADT has been useful in predicting treatment 
outcome before definitive therapy. For example, 
PSADT significantly correlated with biochemical 
recurrence16, linearly correlated with the interval to 
clinical relapse after PSA failure following radiation 
therapy for prostate cancer17, and was the most 
powerful indicator of disease activity in men under 
observation alone.18 When pretreatment variables in 
patients with androgen-independent prostate cancer 
were analyzed to determine the effect on PSA response 
after initiating maximum androgen blockade, 
increased PSADT was the only significant predictor of 
response.19 These results and others have led D’Amico 
to conclude that PSADT is sufficiently robust as a 
surrogate marker of prostate cancer survival to serve 
as a valid endpoint in trials of patients with 
hormone-refractory disease.17 
More recently, PSADT has been used as an 
effective in vivo method for screening nontoxic agents, Int. J. Med. Sci. 2008, 5 
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such as dihydroxyvitamin D3 (calcitriol), that increase 
PSADT without concomitantly decreasing PSA and yet 
become clinically valuable when used in combination 
with other anticancer agents.11 Our results 
demonstrate that oral Apatone significantly increased 
the PSADT of almost all the patients without 
concomitantly decreasing PSA, while 
co-administration of Apatone with known 
chemotherapeutic agents in other cancers resulted in a 
synergistic increase in antitumor activity.8,20 These 
results suggest that Apatone may find use in the clinic 
as a co-adjuvant therapy potentially in addition to 
docetaxol. Our decision not to include patients with 
alkaline phosphatase over 200 U/l may have excluded 
a number of men with osteoblastic bone lesions from 
metastases. This inherent selection bias does not allow 
us to examine the potential role of Apatone as salvage 
therapy, potentially after failure of docetaxol 
chemotherapy in hormone refractory patients.  
Conclusions  
Apatone is safe and effective with thirteen of the 
17 prostate cancer patients having a statistically 
significant (P-value < 0.05) increase in PSADT and a 
decrease in PSADV after taking Apatone for 12 weeks. 
The long-term impact of Apatone on disease 
progression is unknown and remains to be 
demonstrated by further clinical study. Additional 
studies appear warranted for the use of Apatone as a 
co–adjuvant, or for emerging salvage chemotherapy in 
the treatment of late stage prostate cancer. 
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